Investigation of the Levels of Serum Amyloid A, YKL-40, and Pentraxin-3 in Patients with Familial Mediterranean Fever

被引:8
作者
Ciftci, Sefa [1 ]
Celik, Huseyin Tugrul [2 ]
Atukeren, Pinar [3 ]
Ciftci, Nurdan [4 ]
Deniz, Mustafa Saygin [5 ]
Yavuz, Yasemin Coskun [6 ]
Kazanci, Fatmanur Hacievliyagil [2 ]
Gok, Sumeyye [2 ]
Demirin, Hilmi [2 ]
Yigitoglu, Muhammet Ramazan [2 ]
机构
[1] Turkiye Yuksek Ihtisas Training & Res Hosp, Dept Biochem, Kizilay St, TR-06230 Ankara, Turkey
[2] Turgut Ozal Univ, Dept Biochem, Fac Med, Ankara, Turkey
[3] Istanbul Univ, Dept Biochem, Cerrahpasa Fac Med, Istanbul, Turkey
[4] Ankara Educ & Res Hosp, Dept Pediat, Ankara, Turkey
[5] Sutcu Imam Univ, Dept Internal Med, Fac Med, Kahramanmaras, Turkey
[6] Erzurum Reg Training & Res Hosp, Dept Nephrol, Erzurum, Turkey
关键词
Familial Mediterranean Fever; inflammation; PTX-3; Serum Amyloid A; YKL-40; BIOMARKER; DISEASE; MANAGEMENT; DIAGNOSIS; SEVERITY; MARKER;
D O I
10.1002/jcla.21997
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BackgroundFamilial Mediterranean Fever (FMF) is an autosomal recessive form of recurrent episodes of fever and an autoinflammatory disease characterized by inflammation of the serous membranes. The clinical diagnosis is supported by the laboratory findings. This study investigated the relationship of Serum Amyloid A (SAA), YKL-40, and Pentraxin-3 (PTX-3) with the FMF disease. MethodsAbout 50 patients with FMF were enrolled in this study. Patients were divided into three groups according to disease severity score (mild, moderate, and severe). Thirty-seven healthy individuals were included as the control group. Serum SAA, YKL-40, and PTX-3 concentrations were measured using an ELISA kit. ResultsSerum SAA and YKL-40 levels of FMF patients were significantly higher than in the control (P < 0.001). PTX-3 levels were found to be higher in patients even though there was no significant difference (P = 0.113). Whereas the positive predictive value was 71.9% for cut-off point of SAA, the positive predictive value was 83.3% for cut-off point of YKL-40. Whereas a significant correlation was detected in SAA and PTX-3 with YKL-40 (respectively; P = 0.036, P < 0.001), there was no correlation between the PTX-3 with SAA (P = 0.219). ConclusionsYKL-40 can be used together with SAA to support the diagnosis of FMF and to monitor the severity of the disease. In this study, YKL-40 levels were examined for the first time in FMF patients and further studies are necessary using larger patient samples.
引用
收藏
页码:1158 / 1163
页数:6
相关论文
共 36 条
  • [1] Ablij Hans, 2002, Eur J Intern Med, V13, P412, DOI 10.1016/S0953-6205(02)00132-2
  • [2] Familial Mediterranean fever
    Bakkaloglu, A
    [J]. PEDIATRIC NEPHROLOGY, 2003, 18 (09) : 853 - 859
  • [3] Chronic inflammation in FmF: markers, risk factors, outcomes and therapy
    Ben-Zvi, Ilan
    Livneh, Avi
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2011, 7 (02) : 105 - 112
  • [4] A single testing of serum amyloid A levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever
    Berkun, Yackov
    Padeh, Shai
    Reichman, Brian
    Zaks, Nurit
    Rabinovich, Einar
    Lidar, Merav
    Shainberg, Bracha
    Livneh, Avi
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2007, 37 (03) : 182 - 188
  • [5] Genetics and new treatment modalities for familial Mediterranean fever
    Bhat, Anupama
    Naguwa, Stanley M.
    Gershwin, M. Eric
    [J]. AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 201 - 208
  • [6] Bilginer Y, 2006, TURKIYE KLIN J INT M, V2, P33
  • [7] Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy
    Chae, Jae J.
    Aksentijevich, Ivona
    Kastner, Daniel L.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (05) : 467 - 478
  • [8] Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus
    Cieslik, Pawel
    Hrycek, Antoni
    [J]. AUTOIMMUNITY, 2015, 48 (04) : 242 - 250
  • [9] Duzova A, 2006, TURKIYE KLIN J INT M, V2, P12
  • [10] Erdogan O, 2002, T KLIN J PEDIAT, V11, P160